Want to see IN:ONESOURCE full AI Analyst Report?
ONESOURCE Stock Chart & Stats
₹1540.35
--
Market closed
₹1540.35
--
Day’s Range― - ―
52-Week Range₹1,075.00 - ₹2,082.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.94K
Market Cap
₹186.37B
Enterprise Value₹199.46B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹12.95B
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 10, 2026EPS Estimate
5.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,645,800
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.15
Revenue Forecast (FY)₹22.08B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Acceleration (FY2026)A ~77% revenue surge in FY2026 shows meaningful top-line acceleration after a flat FY2025, indicating the company can win customers or scale products. Durable revenue growth expands the addressable base and provides a platform to amortize fixed costs and invest in R&D or commercialization over months.
Historically Low Leverage / Equity BaseA historically low debt-to-equity (~0.16) and sizeable equity base give the firm financial flexibility to absorb short-term losses without immediate liquidity stress. This balance-sheet strength supports funding of biotech development cycles and strategic investments over the coming 2–6 months.
Operational Scale (employee Base)A 1,412-strong workforce in biotech reflects operational scale across R&D, manufacturing, and commercial functions. That scale supports faster product development, regulatory work and commercialization capability, improving the firm's ability to convert research and revenue momentum into durable business outcomes.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow across two years, deteriorating in FY2026, indicates the business is burning cash to run and grow. That structural cash burn forces reliance on external financing, risks dilution or higher borrowing costs, and constrains reinvestment unless cash generation reverses.
Material Profitability DeteriorationShifting from near breakeven to a large net loss and weaker EBIT represents a material deterioration in operating profitability. Persistently negative margins undermine the firm's ability to self-fund growth, reduce resilience to shocks, and increase the odds of cost cutting or strategic reprioritization.
Rising Debt Amid LossesIncreasing debt concurrent with a swing to losses erodes the prior low-leverage cushion. If this trajectory continues, financing costs and covenant pressure could grow, reducing strategic optionality and increasing default or refinancing risk over the medium term.
OneSource Specialty Pharma Limited News
ONESOURCE FAQ
What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1075.00 and its highest was ₹2082.10 in the past 12 months.
What is OneSource Specialty Pharma Limited’s market cap?
OneSource Specialty Pharma Limited’s market cap is ₹186.37B.
When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
OneSource Specialty Pharma Limited’s upcoming earnings report date is Aug 10, 2026 which is in 30 days.
How were OneSource Specialty Pharma Limited’s earnings last quarter?
OneSource Specialty Pharma Limited released its earnings results on May 13, 2026. The company reported ₹0.4 earnings per share for the quarter, the consensus estimate of ₹0.4 by ₹0.
Is OneSource Specialty Pharma Limited overvalued?
According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Overvalued.
Does OneSource Specialty Pharma Limited pay dividends?
OneSource Specialty Pharma Limited does not currently pay dividends.
What is OneSource Specialty Pharma Limited’s EPS estimate?
OneSource Specialty Pharma Limited’s EPS estimate is 5.3.
How many shares outstanding does OneSource Specialty Pharma Limited have?
OneSource Specialty Pharma Limited has 114,645,800 shares outstanding.
What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
OneSource Specialty Pharma Limited reported an EPS of ₹0.4 in its last earnings report, expectations of ₹0.4. Following the earnings report the stock price went down -2.34%.
Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
Currently, no hedge funds are holding shares in IN:ONESOURCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Technical Analysis
Alembic Pharmaceuticals Limited
―
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
PFIZER LIMITED
―
Piramal Pharma Limited
―